Psoriasis

The POETYK PSO LTE trial found deucravacitinib effective in sustaining PASI 75 and PASI 90 responses.

VYNE has initiated a phase 1b trial for its oral BD2-selective BET inhibitor.

Hispanic and non-White patients with psoriatic arthritis (PsA) had higher tender joint counts and greater disease severity, highlighting racial and ethnic disparities in PsA disease burden and treatment outcomes.

Advances in biologics, JAK inhibitors, and PDE4 inhibitors provide personalized options for psoriasis management.

A holistic yet time-efficient approach can help dermatologists recognize early joint pain symptoms associated with psoriasis.

New data reveals an unmet need in the management of moderate to severe psoriasis in Greek patients.

The new dose offers a more tailored and convenient option for patients with inflammatory conditions.

Following his presentation at Winter Clinical Miami, Del Rosso spoke to Dermatology Times about the current treatment landscape of psoriasis.

The IL-36R antagonist has demonstrated its safety and efficacy for generalized pustular psoriasis in GEMINI-1 and GEMINI-2 studies.

At the Horizons in Advanced Practice meeting, Douglas DiRuggiero, DMSc, MHS, PA-C, presented a case of a man aged 47 years with a history of moderate psoriasis for 3 years and a recent diagnosis of psoriatic arthritis

At the Horizons in Advanced Practice meeting, Omar Noor, MD, FAAD, presented a case of a man aged 70 years with a 20-year history of psoriasis who was previously treated with adalimumab.

These efficacy results and safety profile confirm what was observed in phase 1 study.

A recent study found chronic inflammation in psoriasis may contribute to cognitive decline.

In a real-world study, 10 children with generalized pustular psoriasis saw sustained improvements up to 160 weeks.

The new dosing option offers convenience for those managing plaque psoriasis, PsA, and hidradenitis suppurativa.

CD19 CAR T-cell therapy may modulate immune dysregulation in underlying diseases such as psoriasis.

Explore systemic psoriasis management, covering obesity, depression, biologics, and innovative treatment approaches.

As 2023 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in psoriasis this year.

Experts discussed the challenges of managing GPP and highlight a pivotal study on the subcutaneous formulation of spesolimab, demonstrating its potential to prevent GPP flares and improve patient outcomes despite some limitations.

Michael Lewitt, MD, FAAD, highlighted the importance of personalized care, the decision-making process in psoriasis treatment, and the role of patient education.

Join Dermatology Times’ quarterly editor in chief Christopher Bunick, MD, PhD, as he discusses transformative advances in psoriasis care.

The adalimumab biosimilar had an average persistence of 2.5 years, according to this British study.

Researchers found two-thirds of patients reported no impact of psoriasis on their quality of life after 52 weeks of treatment with deucravacitinib.

The effect of insurance status on US patients with psoriasis can help identify those at risk of being undertreated.

Researchers found patients reporting greater disease burden and lower HRQoL are more likely to switch to biologic therapies, regardless of clinician-rated disease severity.